Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Interventional, Cohort Study to Evaluate Long-term Safety of Dupilumab in Patients With Moderate to Severe Asthma Who Completed the TRAVERSE-LTS12551 Clinical Trial

NCT03620747 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT03620747
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03620747 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Interventional, Cohort Study to Evaluate Long-term Safety of Dupilumab in Patients With Moderate to Severe Asthma Who Completed the TRAVERSE-LTS12551 Clinical Trial
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
August 30, 2018
Completion date
February 18, 2022
Enrollment
393 (actual)
Sites
132

Conditions

As the registry lists them; a condition with its own page is linked.

asthma